Fetal growth delay caused by loss of non-canonical imprinting is resolved late in pregnancy and culminates in offspring overgrowth
Abstract
Germline epigenetic programming, including genomic imprinting, substantially influences offspring development. Polycomb Repressive Complex 2 (PRC2) plays an important role in Histone 3 Lysine 27 trimethylation (H3K27me3)-dependent imprinting, loss of which leads to growth and developmental changes in mouse offspring. In this study, we show that offspring from mouse oocytes lacking the PRC2 protein Embryonic Ectoderm Development (EED) were initially developmentally delayed, characterised by low blastocyst cell counts and substantial growth delay in mid-gestation embryos. This initial developmental delay was resolved as offspring underwent accelerated fetal development and growth in late gestation resulting in offspring that were similar stage and weight to controls at birth. The accelerated development and growth in offspring from Eed-null oocytes was associated with remodelling of the placenta, which involved an increase in fetal and maternal tissue size, conspicuous expansion of the glycogen-enriched cell population, and delayed parturition. Despite placental remodelling and accelerated offspring fetal growth and development, placental efficiency, and fetal blood glucose levels were low, and the fetal blood metabolome was unchanged. Moreover, while expression of the H3K27me3-imprinted gene and amino acid transporter Slc38a4 was increased, fetal blood levels of individual amino acids were similar to controls, indicating that placental amino acid transport was not enhanced. Genome-wide analyses identified extensive transcriptional dysregulation and DNA methylation changes in affected placentas, including a range of imprinted and non-imprinted genes. Together, while deletion of Eed in growing oocytes resulted in fetal growth and developmental delay and placental hyperplasia, our data indicate a remarkable capacity for offspring fetal growth to be normalised despite inefficient placental function and the loss of H3K27me3-dependent genomic imprinting.
Editor's evaluation
This important study shows that a lack of Polycomb-dependent epigenetic programming in the oocyte and early embryo influences the developmental trajectory through gestation in the mouse. The authors provide convincing evidence for a two-phase outcome of early growth restriction followed by enhancement, addressing previous inconsistencies in the field. The work establishes a link between the function of a protein in oocytes and programming of fetal growth and placental function in late gestation, though the underlying functional relationshsip between increased fetal growth and placental function will require further investigation. This manuscript will interest scientists within the fields of developmental biology and epigenetics.
https://doi.org/10.7554/eLife.81875.sa0Introduction
Epigenetic mechanisms orchestrate tissue development, body patterning, and growth by regulating chromatin accessibility and expression of developmental genes in embryonic and extraembryonic tissues (Maccani and Marsit, 2009; Sun et al., 2021). H3K27me3 is a repressive epigenetic modification catalysed by PRC2, which is composed of the core components, EED, EZH1/2, SUZ12, and RBBP4/7, all of which are essential for histone methyltransferase activity (Pasini et al., 2004; Faust et al., 1995; O’Carroll et al., 2001; Shen et al., 2008; Glancy et al., 2021). Global deletion of any of the individual genes encoding these PRC2 subunits results in embryonic lethality in mice, while conditional deletions of Eed, Ezh2, or Suz12 result in altered patterning and organ function in a range of tissues (Pasini et al., 2004; Prokopuk et al., 2018; Boyer et al., 2006; Hemming et al., 2014; Dudakovic et al., 2015; Majewski et al., 2010; Liu et al., 2019; Sun et al., 2018; Miao et al., 2020). In humans, de novo germline mutations in EED, EZH2, or SUZ12 result in Cohen Gibson, Weaver, and Imagawa-Matsumoto syndromes, which all involve overgrowth, skeletal dysmorphologies, and cognitive abnormalities (Cohen and Gibson, 2016; Tatton-Brown et al., 2011; Cohen et al., 2016; Cooney et al., 2017; Imagawa et al., 2018; Imagawa et al., 2017; Tatton-Brown et al., 2013).
In mouse oocytes, PRC2 is required for non-canonical H3K27me3-imprinting, whereby H3K27me3 silences the maternal allele of several genes resulting in paternal allele-specific expression of the affected genes in pre-implantation embryos and extraembryonic tissues (Hanna and Kelsey, 2021; Inoue et al., 2017). Oocyte-specific deletion of Eed results in loss of H3K27me3-imprinting in preimplantation embryos and extraembryonic ectoderm causing growth restriction and male-biased lethality in mid-gestation offspring (Inoue et al., 2018). In contrast to growth restriction, another study found that postnatal offspring were overgrown following deletion of Eed in oocytes (Prokopuk et al., 2018). Loss of H3K27me3-imprinting in somatic cell nuclear transfer (SCNT) embryos results in placental hyperplasia associated with bi-allelic expression of H3K27me3 imprinted genes, including Xist, Slc38a4, a micro-RNA cluster within Sfmbt2 (C2MC), Gab1, and Smoc1 (Matoba et al., 2018; Inoue et al., 2020; Wang et al., 2020; Xie et al., 2022; Matoba et al., 2022). Moreover, deletion of Eed in oocytes caused placental hyperplasia and placental hyperplasia was partially or completely rescued by homozygous deletion of Slc38a4 or Sfmbt2 together with Eed in oocytes. In addition, homozygous maternal deletion of Xist and Eed rescued male-biased lethality and partially rescued developmental delay and survival in offspring (Matoba et al., 2022).
Here, we show that loss of EED in the oocyte results in initial fetal growth restriction followed by fetal growth recovery and perinatal offspring overgrowth. While fetuses derived from Eed-null oocytes were initially developmentally delayed and growth restricted, they underwent accelerated growth and development facilitating the birth of pups at normal weight from pregnancies of normal gestational length. Moreover, remedial fetal growth occurred in the presence of placental hyperplasia, reduced placental efficiency, low fetal blood glucose, and normal fetal blood amino acid and metabolite levels. Together, this work reveals a complicated offspring growth trajectory that involved in utero resolution of fetal growth restriction and developmental delay, followed by perinatal overgrowth, despite the loss of H3K27me3-dependent imprinting caused by Eed deletion in oocytes.
Results
Loss of maternal EED compromised mid-gestation survival in offspring
Previous studies demonstrated that deletion of Eed in oocytes resulted in contradictory findings of early embryonic developmental delay (Inoue et al., 2018) and early postnatal offspring overgrowth (Prokopuk et al., 2018). To understand how these outcomes are realised, C57BL/6 Eedfl/fl or Eedfl/wt females were mated to males that were transgenic for Zp3Cre to generate females producing Eed wild-type (wt), Eed heterozygous (het), or Eed-homozygous null (hom) oocytes (Prokopuk et al., 2018). Mating of these females to isogenic C57BL/6 wt males allowed us to generate isogenic wild-type or heterozygous offspring as previously described (Figure 1A; Prokopuk et al., 2018). Heterozygous offspring generated from Eed heterozygous oocytes (HET-het offspring) or from Eed homozygous null oocytes (HET-hom offspring) are isogenic. However, the HET-hom offspring were generated from oocytes that completely lacked functional EED and the HET-het offspring were generated from oocytes that had one functional copy of EED and maintained essentially normal gene repression (Prokopuk et al., 2018; Jarred et al., 2022). As they are isogenic and heterozygous for Eed, comparison of HET-hom with HET-het offspring allowed the identification of differences that resulted specifically from a loss of EED in oocytes in the absence of confounding genetic differences (Figure 1A). In addition, we generated wild-type offspring from Eed-wt and Eed-het oocytes to compare WT-wt and WT-het offspring with HET-het and HET-hom offspring, providing controls for differences generated by Eed heterozygosity in offspring (Figure 1A).
We used automated time-lapse imaging of individual embryos derived from Eed-wt and Eed-hom oocytes to track development from zygote to hatched blastocyst stages. Embryos from Eed-hom oocytes reached the two cell stage 1.08 hr earlier than embryos from Eed-wt oocytes (Figure 1B), but blastocyst expansion and hatching took 2.67 hr longer in HET-hom compared to WT-wt embryos (Figure 1C). All other developmental milestones to blastocyst stage were similar between genotypes (Figure 1B). Although, viability to blastocyst stage was lower in embryos from females producing Eed-hom compared to Eed-wt oocytes (72.17% vs 88.67%, Figure 1D), the proportion of expanded and hatched blastocyst stage embryos did not differ significantly (Figure 1—figure supplement 1A).
To determine whether the cell content of expanded blastocysts was affected, we performed cell counts in whole blastocysts at the end of the culture period using differential staining of the inner cell mass (ICM) and trophectoderm (TE) cells (Gardner and Lane, 2014; Figure 1—figure supplement 1B). This revealed that the overall cell content of embryos from Eed-hom females was lower than in Eed-wt controls (Figure 1E). The number of TE cells was not significantly altered, but the ICM contained fewer cells in HET-hom embryos compared to WT-wt controls (Figure 1F; Figure 1—figure supplement 1C), indicating that the ICM was smaller in embryos from oocytes that lacked EED compared to oocytes that maintained EED function (Figure 1F). As previous reports indicated that maternal deletion of Eed did not compromise development to the blastocyst stage, or cause apoptosis in blastocysts (Inoue et al., 2018), it is likely that lower proliferation explains the reduction we observed in blastocyst cell number, which affected the ICM rather than the TE.
To assess the effect of oocyte-specific Eed deletion on fetal survival and throughout pregnancy, we compared the number of live fetuses and litter size in offspring generated from Eed-hom, Eed-het, and Eed-wt oocytes at multiple stages during gestation and after birth. Using Zp3Cre to delete Eed in oocytes, we found no difference between genotypes in the number of implantations of live embryos in four pregnancies from Eed-null oocytes analysed at embryonic day (E)9.5 (Figure 1G), indicating that HET-hom preimplantation embryos implanted at similar rates and progressed through gastrulation. However, consistent with previous findings (Glancy et al., 2021; Hanna and Kelsey, 2021), the number of live fetuses at E12.5, E14.5, E17.5, and the number of live born pups was significantly lower for Eed-hom mothers than for Eed-het and Eed-wt control females (Figure 1G). In addition, 71.43% of live fetuses in E17.5 Eed-hom pregnancies were female, indicating male-biased lethality of HET-hom offspring (Figure 1H), consistent with previous studies (Inoue et al., 2018; Harris et al., 2019).
Loss of EED in oocytes results in developmental delay followed by fetal growth recovery and postnatal overgrowth
While a previous study observed that deletion of Eed in oocytes caused embryo loss by E6.5 (Matoba et al., 2018), we observed loss of HET-hom offspring between E9.5 and E12.5, indicating that embryo survival and/or placental function was compromised. We, therefore, assessed growth and development of surviving mid-late gestation offspring. At E9.5, HET-hom offspring were small compared to WT-wt offspring (Figure 2A) and combined offspring and extraembryonic tissue weights were significantly lower than HET-het, WT-het, and WT-wt controls (Figure 2—figure supplement 1A). At E12.5 HET-hom embryos contained fewer tail somites and had delayed inter-digital tissue regression in foot plates at E14.5 compared to HET-het, WT-het, and WT-wt controls (Figure 2B, Figure 2—figure supplement 1B), demonstrating that HET-hom growth and development were retarded during early-mid gestation development.
As in utero developmental delay contrasted markedly with our previous observation that P2 HET-hom offspring were overgrown (Prokopuk et al., 2018) we examined the temporal trajectory of HET-hom offspring by measuring fetal weight at E12.5, E14.5, E17.5, and E18.5 and pup weight on the day of birth (P0) and at P3. HET-hom offspring were significantly lighter than HET-het, WT-het, and WT-wt controls at E12.5, E14.5, E17.5, and E18.5, but by P0 and P3 HET-hom offspring were heavier than isogenic HET-het controls (Figure 2C–H). However, by monitoring plug date and delivery day, we also observed that gestational length was extended in 60% of pregnancies from Eed-hom oocytes. Of 23 litters, 9 (40%) were born on E19.5, 7 (30%) were born on E20.5, and 7 (30%) were born on E21.5. While all pups born on E19.5 survived, 30% and 67% of offspring from pregnancies extended by one or two days respectively, were found dead. In contrast, although one litter from an Eed-het pregnancy was delivered on E20.5, 23 (9 wt and 14 het) were delivered on E19.5 (Figure 2I).
To determine if the extended gestational length of pregnancies from Eed-hom oocytes affected HET-hom offspring weight, we examined pup weight in pregnancies delivered on E19.5 only. This revealed that HET-hom offspring delivered on E19.5 were similar in weight and developmental stage to controls (Figure 2J). Moreover, comparison of data for all surviving HET-hom pups delivered on E19.5-E21.5 (Figure 2G) with those only born on E19.5 (Figure 2J) revealed that increased gestational length contributed to the overall increased pup weight of the population at P3 (Figure 2H). However, ratios of HET-hom fetal weight over WT-wt, WT-het, or HET-het fetal weight at E12.5, E14.5, E17.5, E18.5, and E19.5 (excluding litters of extended gestational length) revealed that the weight deficit in HET-hom was resolved between E14.5 and birth on E19.5 (Figure 2L). Moreover, with the exception of the modest weight deficit, E18.5 HET-hom offspring were indistinguishable from controls at the gross morphological level. Together, these data demonstrate that the gross morphological delay and the fetal weight deficit in HET-hom offspring was resolved by E19.5 and that this occurred independently of litter size. In addition, by P3 HET-hom offspring were heavier than controls. As the overgrown HET-hom offspring in the P3 weight cohort (Figure 2H) included litters born at E19.5 E20.5 and E21.5, both postnatal offspring growth and extended gestation presumably contributed to the overgrowth phenotype.
We also observed increased fetal resorptions and fetal death (Figure 2—figure supplement 1C), raising the possibility that the reduced number of fetuses/pregnancy might result in greater maternal support per fetus leading to normalisation of pup weight at E19.5 (Prokopuk et al., 2018). However, there was no difference in pup weight from Eed-hom and control litters that contained 5–7 pups and were born on E19.5 (Figure 2K), indicating that resolution of fetal growth restriction in utero was at least partly independent of litter size, a finding consistent with our earlier study (Prokopuk et al., 2018). Combined, while HET-hom offspring were initially developmentally delayed and under-weight compared to their isogenic heterozygous counterparts and wild-type controls, HET-hom offspring weight was normalised by birth, and pups were overgrown by P3 (Figure 2J and K), an outcome facilitated by fetal growth recovery and extended gestation.
Oocyte-specific loss of EED results in placental hyperplasia and reduced placental efficiency
To understand whether the normalisation of HET-hom fetal weight might be related to changes in placental development, we collected and weighed E12.5, E14.5, E17.5, and E18.5 placentas from HET-hom, HET-het, WT-het, and WT-wt offspring. At E12.5 placental weights were consistent across all genotypes, but at E14.5 HET-hom placentas were slightly heavier than HET-het controls (Figure 3A–B). By E17.5 HET-hom placentas were 58% heavier than HET-het controls (Figure 3C), and at E18.5 HET-hom placentas were 24% heavier than HET-het placentas (Figure 3D). These changes were reflected in differing HET-hom and HET-het placental growth rates over time with HET-hom placenta growth rates 0.79 and 1.81 times greater than HET-het placentas between E12.5 and E14.5 and E14.5 and E17.5, respectively (Figure 3E–F). Comparison of HET-hom placental to fetal weights revealed that placental growth preceded late-gestational fetal growth (Figure 3E–F). The HET-hom fetal growth rate was slightly lower than HET-het offspring between E12.5 and E14.5, similar between E14.5 and E18.5, but was greater between E18.5 and E19.5 so that HET-hom pups were of equivalent weight to controls at birth on E19.5 (excluding litters with extended gestation; Figures 2C–F, J–3E and G). To further understand the relationship between placental function and offspring growth, we calculated the offspring body to placental weight ratio, which is indicative of placental efficiency (Krombeen et al., 2019). By this measure, placental efficiency was reduced at E12.5, E14.5, E17.5, and E18.5 in HET-hom offspring compared to all other genotypes (Figure 3H–K).
Loss of EED in the oocyte results in altered developmental patterning of the placenta
While we observed male-biased fetal loss and that E17.5 HET-hom placentas substantially differed from controls, our data revealed that male and female fetuses and placentas were of similar weights at E14.5 and E17.5 (Figure 3—figure supplement 1A–D). To examine male and female placental development in more detail we stained sections from the midline of the placenta with periodic shiff (PAS; Figure 3L) and hematoxylin and eosin (H&E; Figure 4A–B) and used QuPath to quantify placental, junctional zone, decidua areas, and glycogen-enriched cells. To ensure comparative analyses between individuals, we examined sections from the middle of the placentas from E14.5 and E17.5 male and female WT-wt, WT-het, HET-het, and HET-hom offspring. Comparison of male and female samples revealed no sex-specific differences in placental weight or cross-sectional areas of placenta, decidua, or junctional zone, but the cross-sectional areas of placenta, junctional zone, and decidua were increased in HET-hom placentas (Figure 3—figure supplement 1C–G). Interestingly, this lack of sex-specific differences was consistent with similar fetal and placental weight between males and females (Figure 3—figure supplement 1A–D), indicating that male-biased lethality (Figure 1H) was independent of obvious sex-specific changes in the placenta or fetal growth rate.
Given the lack of sex-specific changes in placental weight or cross-sectional areas (Figure 3—figure supplement 1), we analysed male and female samples together. H&E and PAS staining indicated that the junctional zone was expanded in HET-hom placentas, with abnormal projections of PAS-stained spongiotrophoblast cells into the labyrinth (Figures 3L and 4A). Consistent with the modest increase in weight of HET-hom compared to HET-het placentas at E14.5 (Figure 3B), there was a 19% increase in cross-sectional area of HET-hom compared to HET-het controls (Figure 4—figure supplement 1A). This difference was emphasised at E17.5, with a 56% increase in HET-hom placental cross-sectional area compared to HET-het controls (Figure 4B–C). At E14.5, junctional zone area was significantly larger in HET-hom placentas compared to the WT-wt and HET-het controls, however, there was no difference in the HET-hom decidua area compared to all other genotypes (Figure 4—figure supplement 1B–C). At E17.5, the overall HET-hom placental cross-sectional area was greater than that of HET-het and WT-wt controls (Figure 4C), including increased total area in the junctional zone and decidua (Figure 4—figure supplement 1D–E). However, as a proportion of the total placental area, the junctional zone was significantly larger, resulting in a higher junctional zone/placental ratio but a similar decidua/placental ratio in HET-hom placentas compared to other genotypes (Figure 4D–E). As H&E and PAS staining indicated that junctional zone was expanded, we used QuPath to determine glycogen cell number and areas occupied by glycogen-enriched cells and non-glycogen cells. The total glycogen cell count was increased in HET-hom placentas but was similarly higher in both sexes (Figure 4F, Figure 4—figure supplement 1F). Moreover, the area occupied by glycogen and non-glycogen cells was increased in the decidua and junctional zones (Figure 4G–J). Together, while the whole HET-hom placenta was larger than controls, the fetally-derived junctional zone was disproportionately expanded and there were significantly more PAS-stained glycogen-enriched cells in midline sections of HET-hom placentas compared to all other genotypes.
As glycogen can be converted to glucose, to determine whether the greater number of glycogen-enriched cells might impact glucose levels in HET-hom offspring, we measured blood glucose levels at E17.5 and E18.5, just prior to parturition. Fetal blood glucose level was initially relatively low and similar in all genotypes at E17.5 (Figure 4K), but increased significantly in WT-wt, HET-wt, and HET-het controls by E18.5. However, the fetal blood glucose level in HET-hom offspring did not increase between E17.5 and E18.5 and were lower than controls at E18.5 (Figure 4K). This indicated that increased circulating glucose was unlikely to explain the accelerated HET-hom fetal growth observed during late gestation.
To determine whether increased fetal capillary area within the labyrinth might underlie a greater potential for maternal-fetal nutrient exchange we performed IF for CD31 (PECAM-1). Sections taken from the middle of each placenta were stained and the total labyrinth area, labyrinth/placental ratio, and fetal capillary/labyrinth ratio were quantified in WT-wt, HET-het, and HET-hom placentas (Figure 5A–B). In this analysis the labyrinth was defined by the CD31-positive capillary enriched region for each genotype and the total labyrinth area was defined as capillary area plus the total space outside the capillaries. The capillary area was defined as the total CD31 positive area plus the unstained space inside the capillaries. HALO analysis revealed a reduction in overall labyrinth area in both HET-het and HET-hom placentas compared to WT-wt controls (Figure 5C), indicating that heterozygosity for Eed reduced labyrinth size in the placenta. However, when total placental size was taken into account, the labyrinth/placental ratio was decreased only in HET-hom placentas compared to WT-wt and HET-het controls (Figure 5D). Moreover, while the capillary area to labyrinth area ratio was unchanged in HET-hom placentas compared to WT-wt controls, this ratio was reduced in HET-hom compared to HET-het placentas (Figure 5E). Together, these data indicate that the area available for maternal-fetal nutrient transfer in the labyrinth of HET-hom placentas was either unaffected or decreased compared to controls.
Widespread gene dysregulation occurs in placentas from Eed-hom oocytes
As the developmental changes observed in the placenta indicated that transcriptional regulation may be altered in HET-hom placentas, we analysed male and female placental tissue from E17.5 HET-hom, HET-het, and WT-wt offspring using RNA-sequencing (RNA-seq). We recovered >20 million clean, mappable reads per sample and analysed 4–6 samples for all genotypes and sexes except male HET-hom, for which only three samples were available. Principal component analysis (PCA) revealed that female HET-hom placental gene expression differed from HET-het and WT-wt placental transcriptomes (Figure 6A). Supporting this, differential gene expression analysis using an FDR <0.05 (false discovery rate) revealed 2083 differentially expressed genes (DEGs; together referred to as Eed placental DEGs) between HET-hom vs HET-het placentas (Figure 6B, Supplementary file 1A) and only four DEGs (Eed, Fibin, Hapln4, & Dtx1) between HET-het and WT-wt placentas. Together, this indicated that loss of Eed in oocytes rather than heterozygosity of Eed in offspring caused the vast majority of transcriptional dysregulation in HET-hom placentas. Gene ontology analysis indicated that the Eed DEGs identified between female HET-hom and HET-het placentas regulate morphogenesis, system development, and multicellular organism development (Figure 6C), suggesting that the gene dysregulation observed influences a diverse range of systems and processes. Surprisingly, PCA revealed that male HET-hom placental transcriptomes were similar to HET-het and WT-wt controls (Figure 6—figure supplement 1A), with only one sequence (CAAA01077340.1) differentially expressed between male HET-hom and HET-het placentas (FDR <0.05). However, comparison of the male and female RNA-seq data without FDR correction identified 478 male DEGs and 3964 female DEGs between HET-het and HET-hom placentas. Of these 227 were common to male and female placentas indicating that they were commonly dysregulated in male and female placentas but the impact in male placentas was potentially less pronounced (Figure 6—figure supplement 1B; Supplementary file 1B-D).
By E14.5 the majority of mature placental cell types and their key cell specific transcriptional programs are established (Woods et al., 2018). As single-cell RNA-seq data from E14.5 C57BL/6 placentas was publicly available (Han et al., 2018), we used these data to gain an indication of the placental cell types in which gene dysregulation occurred in female HET-hom placentas. Of the 2083 Eed placental DEGs identified in female HET-hom placentas, 543 genes were found in the E14.5 mouse placental data set (Han et al., 2018; Supplementary file 1E). Cell-specific comparisons revealed that of these 543 genes, 166 Eed female placental DEGs included genes preferentially expressed in the junctional zone, 57 Eed female placental DEGs were preferentially transcribed in the labyrinth and 104 Eed female placental DEGs were preferentially transcribed in the maternally derived decidua. For ease of reference, these were respectively defined as ‘Eed junctional zone DEGs,’ ‘Eed labyrinth DEGs,’ and ‘Eed decidua DEGs’ (Figure 6—figure supplement 2A–C, Supplementary file 1E). Together these data revealed that gene dysregulation in HET-hom placentas was not isolated to a single region, and that both maternal and fetal-derived cells were altered. Of the Eed junctional zone DEGs 86% were upregulated, whereas 86% and 97% of the Eed labyrinth DEGs and Eed decidua DEGs were downregulated, respectively (Figure 6—figure supplement 2D–F, Supplementary file 1E). Together, these data demonstrate a strong bias for up-regulation of genes expressed in the junctional zone layer of the Eed placenta, which likely reflects the significant expansion observed in the junctional zone as a proportion of the total placental size.
Eed placental DEGs included non-imprinted genes, H3K27me3 and classically imprinted genes, and a small number of X-linked genes
The majority (2029/2083; 97.4%) of placental DEGs were bi-allelically expressed autosomal genes that are associated with a range of developmental processes (Figure 6C–E). In addition, of 76 candidate non-canonical H3K27me3 imprinted genes identified by Inoue et al., 2017, 16 were dysregulated in HET-hom vs HET-het placentas, though eight of these genes were also listed as classically imprinted genes in the list we examined (Figure 6C and F). Notably, Slc38a4, Slc38a1, Sfmbt2, Gab1, and Smoc1 are normally paternally expressed (maternally imprinted/silenced), but were upregulated in female HET-hom placentas consistent with de-repression of the maternal allele (Figure 6F, Supplementary file 1F). Loss of H3K27me3-dependent imprinting at these genes has been functionally linked to placental hyperplasia, including in offspring derived from SCNT (Inoue et al., 2020; Wang et al., 2020; Xie et al., 2022; Matoba et al., 2022). Given that both Eed HET-hom offspring and SCNT offspring lack H3K27me3 imprinting, we compared E14.5 and E19.5 fetal and placental weight data collected in this study with SCNT offspring data extracted from Matoba et al., 2018. This revealed very similar fetal and placental growth trajectories in the Eed HET-hom and SCNT offspring models (Figure 7).
Of the remaining DEGs listed as H3K27me3 imprinted genes (Figure 6F), only Slc38a1 is usually paternally expressed. The remainder are either maternally or bi-allelically expressed indicating that they are unlikely to be regulated by H3K27me3 imprinting in oocytes. In addition to H3K27me3 imprinted genes, classically imprinted genes were also dysregulated in HET-hom placentas. Of 325 candidate or confirmed classically imprinted genes we examined (Andergassen et al., 2017; Wanigasuriya et al., 2020), 22 were increased in expression including 15 paternally expressed (maternally imprinted/silenced) and seven maternally expressed (paternally imprinted/silenced) genes (Figure 6G, Supplementary file 1F). Three (Gab1, Sfmbt2, and Smoc1) of the upregulated paternally expressed genes were also identified in our analysis of H3K27me3 imprinted genes. Similarly, of 24 genes that were decreased in expression, 17 are normally maternally expressed and seven are paternally expressed genes (Figure 6G, Supplementary file 1F).
Maternal EED is required for regulating X-inactivation in pre-implantation embryos and loss of EED in oocytes causes male-biased HET-hom fetal lethality (Figure 1H; Inoue et al., 2018; Harris et al., 2019). Moreover, loss of H3K27me3 imprinting increases maternal Xist expression and deletion of maternal Xist partially rescued growth delay caused by loss of EED in oocytes (Matoba et al., 2022). Xist was not significantly increased in HET-hom placentas in this study. However, the X-linked genes Plac1 and Ldoc1 were increased in female HET-hom compared to HET-het placentas but were not differentially expressed in male placentas raising the possibility that these genes escape X-inactivation in Het-hom placentas (Supplementary file 1B-D). In line with its increased transcription, PLAC1 protein was also increased in cells within the junctional zone (Figure 6H, Figure 6—figure supplement 3). These data are of interest as together with the imprinted genes Ascl2 and Peg3, Plac1, and Ldoc1 are known to regulate placental glycogen stores (Tunster et al., 2020) and have been associated with junctional zone development (Tunster et al., 2016; Tunster et al., 2018; Lee et al., 2015; Allas et al., 2019; Thiaville et al., 2013; Naruse et al., 2014). Despite the increased expression of this subset of X-linked genes, placental DEGs occurred at a similar rate on the X-chromosome (p=0.26626) and autosomes (Supplementary file 1G). Moreover, while there were 81 X-linked DEGs, 32 had increased and 49 had reduced expression (Supplementary file 1A) indicating that there was no bias for increased expression of X-linked genes in HET-hom placentas. However, there was a significant overrepresentation of genes located on chromosomes 6 (p=0.000375) and 15 (p=0.03088) genes encoded by the mitochondrial genome (p=0.00202) in the DEG list (Supplementary file 1G). Included in the mitochondrial sequences were mt-Co1, mt-Co2, and mt-Co3 (mitochondrial cytochrome oxidase C I-III), mt-Nd3, mt-Nd4, and mt-Nd4l (mitochondrial NADH dehydrogenase 3 and 4), and mt-Atp6 (mitochondrial ATP synthase 6). These are of interest given that mitochondrial function is dysregulated in placentas with compromised function (Colson et al., 2021).
DNA methylation changes in E17.5 placentas are found at a subset of DEGs
While loss of EED in oocytes disrupts H3K27me3 imprints (Hanna and Kelsey, 2021; Inoue et al., 2017), our data suggest that other genes may also be affected, perhaps through altered DNA methylation (Jarred et al., 2022). We, therefore, analysed DNA methylation in placentas of E17.5 female WT-wt, HET-het, and HET-hom offspring using RRBS. This identified 81 DMRs between HET-het and HET-hom placentas, 87 DMRs between WT-wt and HET-hom placentas, and 27 DMRs between WT-wt and HET-het placentas (FDR <0.05; Figure 6I; Supplementary file 1H-J). Of the 81 HET-het vs HET-hom DMRs, two were located within or nearby the H3K27me3 imprinted genes Sfmbt2 and Mbnl2. The DMR associated with Sfmbt2 was 25% methylated in the HET-het placentas but 10% methylated in the HET-hom group (Supplementary file 1H), which may explain its increased transcript levels in HET-hom placentas. In addition, of the 81 HET-het vs HET-hom placental DMRs, seven were within 1 kb of the orthologous human region that had H3K27me3 peaks in human oocytes (Xia et al., 2019), including one 201 bp upstream of the SFMBT2 transcriptional start site.
Also included in the 81 HET-het vs HET-hom placental DMRs were four within or nearby the classically imprinted genes Igf2r, Airn, Peg10, Sgce, Jade1, and 2410003L11Rik, and 74 DMRs at non-imprinted loci. The latter included five DMRs within or nearby eight non-imprinted genes (Ntn1, Unc45b, Fam83h, Tiam1, Pcdhga1, Pcdhga5, Pcdhgb5, and Pcdhgb7) that were differentially expressed between HET-het and HET-hom placentas (Figure 6I; Supplementary file 1G). Of these, NTN1 (Netrin1) is of particular interest as it is reduced in the placentas of women with fetal growth restriction and potentially influences placental size by increasing the viability of placental microvascular endothelial cells (Qian-hua et al., 2011; Wang et al., 2011). While Ntn1 is not imprinted, it had reduced DNA methylation, consistent with its increased transcription in HET-hom compared to HET-het placentas (Supplementary file 1H).
Loss of EED in the oocyte did not alter late gestational fetal blood metabolite levels
A previous study of SCNT-derived mice indicated that loss of non-canonical imprinting increased Slc38a4 expression, resulting in placental hypertrophy and increased amino acid transport (Xie et al., 2022). To determine whether altered placental function changed fetal blood amino acid levels and/or fetal or maternal metabolomic state, we collected blood samples from male and female E17.5 WT-wt, HET-het, and HET-hom fetal offspring and their mothers and assessed 356 metabolites using mass spectrometry. One hundred and sixty metabolites were detected across the sample sets. Principal component analysis revealed three separate clusters corresponding to maternal and fetal blood samples and 19 pooled biological quality control samples (PBQCs: included to ensure data reproducibility), demonstrating sensitivity to detect metabolic differences (Figure 8A). The maternal samples clustered separately from the fetal samples, revealing clear metabolic differences between the fetal and maternal bloods. However, HET-hom and WT-wt or HET-het of both sexes were inseparable using PCA (Figure 8B) and there were no significant differences that were consistent between HET-hom and WT-wt or HET-het fetal blood samples of either sex (FDR <0.05; Figure 8C). For example, while 14 metabolites (10 with a mean difference >0.5) were statistically significant between female HET-hom and HET-het fetal blood samples (Figure 8C, Supplementary file 1K), none of the same metabolites differed between female HET-hom and WT-wt samples (Figure 8C, Supplementary file 1L-M) and there were no differences between male HET-hom and HET-het samples (FDR <0.05; Figure 8C). Given we expect similar changes between HET-het and WT-wt controls compared to HET-hom samples, we concluded that the differences detected were unlikely to be due to altered placental function in HET-hom offspring. Moreover, although differences in levels of several amino acids have been reported in fetal blood samples of SCNT-derived animals (Xie et al., 2022), we detected no consistent differences in amino acids in HET-hom fetal blood samples and their counterpart HET-het and WT-wt controls in either sex (Figure 8D). Phenylalanine was modestly increased in female and male HET-hom vs WT-wt samples, but was unchanged between HET-hom and HET-het samples of either sex (Figure 8D).
Finally, serum metabolites of mothers carrying WT-wt, WT-het/HET-het, and HET-hom pregnancies clustered together. Moreover, no significant differences in metabolites were detected between the genotypes indicating that the blood metabolomes of these females were similar late in pregnancy, despite the substantial differences in placental and fetal growth profiles of the HET-hom offspring (Figure 8A). Together, these data indicate that an increased supply of amino acids or other metabolites across the placenta is unlikely to account for the accelerated growth we observed in late gestational HET-hom offspring.
Discussion
Fetal growth restriction is commonly caused by placental insufficiency investigated using surgical or nutritional interventions in animal models (Palliser et al., 2010; Louey et al., 2000; Swanson and David, 2015; Vuguin, 2007). In this study similar outcomes were caused by deleting Eed in the oocyte, resulting in the production of isogenic HET-hom offspring that are epigenetically different to HET-het controls. Initially, offspring were characterised by embryonic and fetal developmental delay, but this was resolved late in gestation. Despite lower placental efficiency indicated by fetal/placental weight ratio, low fetal glucose levels, and unaffected amino acid and metabolomic profiles in late gestation fetal and maternal serum, HET-hom offspring underwent a period of late fetal growth recovery and early postnatal overgrowth. Although placental transcription and DNA methylation was altered at important H3K27me3-imprinted genes and some classically imprinted genes, transcription and DNA methylation were also altered at many non-imprinted sites. In addition, several X-linked genes that have been associated with placental development and function were transcriptionally increased, but we found no evidence for widespread dysregulation of X-inactivation in late-stage placentas. While the underlying cause remains unclear, our data indicate that fetal growth is normalised in HET-hom offspring in the absence of any obvious increase in nutritional support from the placenta and that loss of EED in oocytes causes programming effects on the fetus that are unlikely to be explained by loss of only H3K37me3-dependent imprinting or increased maternal Xist.
A previous study reported that blastocysts from Eed-null oocytes formed at normal rates and were not affected by increased cell death, indicating normal pre-implantation development (Inoue et al., 2018). However, we found that while preimplantation development progressed at similar rates in embryos from Eed wild-type and Eed-null oocytes, blastocysts derived from Eed-null oocytes contained low cell numbers, primarily due to fewer inner cell mass cells. This deficit may be due to low cell proliferation during pre-implantation development caused by loss of EED-dependent oocyte programming or to loss of maternal EED supplied in the mature oocyte (Inoue et al., 2017; Inoue et al., 2018; Jarred et al., 2022; Harris et al., 2019; Erhardt et al., 2003). While the latter is consistent with the established role of PRC2 in driving cell division in stem cells and other cell types (Bracken et al., 2003), other EED-dependent effects in the oocyte may also contribute.
Consistent with previous studies (Matoba et al., 2018; Xie et al., 2022; Matoba et al., 2022), later development of offspring generated from oocytes lacking EED was characterised by developmental delay of the fetus and placental hyperplasia. Placental hyperplasia results from loss of H3K27me3 imprinting in SCNT and from maternal deletion of Eed (Matoba et al., 2018; Xie et al., 2022; Matoba et al., 2022), demonstrating a common impact on placental development in both models. Moreover, comparison of our data with SCNT offspring (Matoba et al., 2018) indicated that fetal growth restriction and subsequent fetal growth recovery occur in Eed-null oocyte and SCNT-derived offspring, and that this phenotype was resolved during pregnancy. While both models involve loss of H3K27me3-dependent imprinting (Inoue et al., 2018; Wang et al., 2020; Xie et al., 2022), the HET-hom offspring in this study were derived from oocytes that lacked maternal Eed/EED (RNA or protein) and SCNT embryos were derived from wild-type enucleated oocytes that presumably contained maternal PRC2. Therefore, while the lack of maternal EED could explain the lower number of cells observed in Eed HET-hom preimplantation offspring, this is less likely in SCNT embryos. However, early development of SCNT embryos is restricted by the low efficiency of oocyte-driven reprogramming (Wang et al., 2020; Matoba et al., 2014; Liu et al., 2016; Cao et al., 2013), and comparison of the earliest stages of development between these models is challenging. Despite this, growth and developmental delay appear to be resolved late in gestation in both models without correction of H3K27me3-imprinting, indicating a level of plasticity that permits delivery of fully grown pups. Even though prolonged gestation decreased pup survival in the Eed model, an interesting conjecture may be that an unknown sensing mechanism in these growth-restricted pregnancies supports adaptation(s) that lead to late fetal growth and extended gestation, favouring the delivery of viable pups. While speculative, such a mechanism could involve epigenetic adaptation during early or late development and/or altered epigenetic control of imprinted or non-imprinted genes in the placenta and/or fetus.
Placental hyperplasia in HET-hom offspring was characterised by an increased number of glycogen-enriched cells and increased junctional zone and decidua area occupied by glycogen-enriched cells and non-glycogen cells. While increased size was observed particularly in the fetally-derived junctional zone, the maternal side of the placenta also became larger, perhaps facilitating overall tissue balance in the placenta in response to the hyperplastic junctional zone. The number of glycogen-enriched trophoblasts usually peaks at E16.5 and declines by approximately 60% by E18.5 (Tunster et al., 2020), potentially releasing glycogen stores to the mother and/or fetus. Consistent with this, fetal blood glucose levels increased between E17.5 and E18.5 in WT-wt, WT-het, and HET-het control offspring. However, despite the increased numbers of glycogen-enriched cells in HET-hom placentas, fetal blood glucose levels did not significantly increase in HET-hom offspring. Moreover, the decreased fetal/placental weight ratio observed in HET-hom offspring suggested decreased placental efficiency and we did not observe any increase in labyrinth area, or the fetal labyrinth/placenta or capillary/labyrinth ratios, suggesting that the area devoted to maternal-fetal nutrient exchange was not substantially affected. Consistent with this, we found no change in levels of fetal blood amino acids or other metabolites, also suggesting that placental function was not obviously enhanced. Together, increased maternal-fetal placental exchange, glucose, or amino acid supply seem unlikely to explain the ability of substantially growth-restricted HET-hom offspring to attain normal weight by birth, indicating that unknown mechanism(s) contribute.
In addition to facilitating increased glucose release and fetal growth, glycogen-producing trophoblasts are considered to inhibit the release of placental factors such as oxytocin and prolactins, which prepare the pregnancy for parturition (Harris et al., 2019; Lee et al., 2015). Therefore, one possibility may be that the increased glycogen cell number in late-gestation HET-hom placentas inhibits the release of oxytocin, prolactins, or other hormones, causing the delay in parturition observed in 60% of the pregnancies from Eed-hom oocytes. Moreover, while extended gestation may also allow additional time for growth delay to resolve, HET-hom pup mortality increased in pregnancies extended by one or two days, indicating that there is a substantial cost for lengthening pregnancy in this model.
As well as morphological alterations observed in HET-hom placentas, we found extensive transcriptional dysregulation with 2083 DEGs identified between HET-hom and HET-het placentas. Consistent with the increased size of fetal and maternal tissues in HET-hom placentas, comparison of these DEGs with single-cell data from E14.5 normal placentas (Han et al., 2018) indicated that altered gene expression was not restricted to genes normally expressed in a single region of the HET-hom placenta, but affected fetal and maternal layers. While one might expect oocyte-specific loss of EED to affect only fetally-derived placental tissue, this ignores the possibility that increased size of the maternal tissue may occur in response to hyperplasia in the fetally-derived layers. Indeed, it seems plausible that the placenta may not properly support late fetal growth without remodelling maternally-derived placental tissue and inducing associated transcriptional change.
Another study demonstrated that loss of H3K27me3 imprinting of Xist contributes to the fetal developmental delay and male-biased fetal death of offspring derived from Eed-null oocytes (Matoba et al., 2022). Oocyte-specific deletion of both Xist and Eed increased survival from approximately 3–6 pups/litter, but a significant deficit in litter size remained compared to the average of ~8.5 pups in wild-type control litters. Moreover, while Xist/Eed maternal double deletion improved fetal body weight, it remained marginally, but significantly lower than wild-type control. Therefore, while deletion of maternal Xist rescued male-biased fetal death observed as a result of Eed deletion in oocytes, it did not completely restore offspring growth or survival, demonstrating that other mechanisms contribute (Matoba et al., 2022). Moreover, the fetal growth recovery of HET-hom offspring described in our study cannot be explained by loss of Xist, indicating that the mechanism involved in the late gestational resolution of HET-hom fetal growth and development remains unresolved.
The DEGs identified in HET-hom hyperplastic placentas included increased expression of H3K27me3 imprinted genes Slc38a4, Sfmbt2, Gab1, and Smoc1, nine classically imprinted genes, X-linked genes including Plac1, Wdr1, and Ldoc1 and many bi-allelically expressed autosomal genes. Consistent with increased Plac1 transcription, immunohistochemistry confirmed that PLAC1 expression was increased in junctional zone cells in HET-hom placentas. However, rather than increased expression, deletion of Plac1 has been associated with male-biased lethality and a similar placental phenotype to that observed in HET-hom offspring (Jackman et al., 2012). Notwithstanding this difference, it seems likely that placental hyperplasia in HET-hom offspring could involve Plac1, Wdr1, Ldoc1, and/or autosomal genes, perhaps in conjunction with Slc38a4 or Sfmbt2/C2MC, which clearly contribute to placental hyperplasia caused by loss of EED in the oocyte (Matoba et al., 2022).
Comparison of HET-hom with HET-het placentas using RRBS identified 81 DMRs, including H3K27me3 imprinted loci Sfmbt2/C2MC and Mbnl2, five classically imprinted loci and 74 non-imprinted loci, indicating that loss of EED in oocytes affects epigenetic status at both imprinted and non-imprinted genes. However, while HET-hom and HET-het offspring are isogenic and these data demonstrate that DNA methylation changes occur in the placenta as a result of deletion of Eed in oocytes, it is unclear that this is a direct effect. Moreover, as we observed 27 DMRs between HET-het and WT-wt placentas heterozygosity for Eed may also contribute, although only four differentially expressed genes, including Eed, were identified in the same comparison. This supports the idea that perturbation of H3K27me3 in the oocyte leads to altered DNA methylation and transcription of imprinted and non-imprinted genes that are influential in placental function and embryo growth. However, further work is required to determine the extent to which epigenetic changes in the oocyte directly affect embryo and placental development in offspring.
In summary, we demonstrate that loss of PRC2 function in the oocyte results initially in embryonic developmental delay and fetal growth restriction, followed by placental hyperplasia and late fetal growth that results in normalisation of offspring weight at birth and perinatal overgrowth (Figure 9). Moreover, it appears that offspring derived from either Eed-null oocytes or by SCNT have an innate ability to correct fetal growth restriction during the late stages of pregnancy despite maternally inherited impacts mediated by Xist or H3K27me3-dependent imprinting. In offspring from Eed-null oocytes normalisation of fetal growth occurs despite low placental efficiency and in the absence of enhanced glucose, amino acid, and metabolite levels, indicating that unknown mechanisms contribute. Together, this work reveals that altered PRC2-dependent programming in the oocyte elicits a complex intrauterine response that supports compensatory fetal growth despite apparently negative impacts on placental development and function. As fetal growth restriction and fetal catch-up growth have been linked with negative health outcomes later in life, including metabolic conditions (Singhal, 2017; Singhal and Lucas, 2004), this model may provide opportunities for understanding the physiological basis of such outcomes. Moreover, given that mutations in EED, EZH2, and SUZ12 have all been associated with overgrowth and a range of co-morbidities in Cohen-Gibson, Weaver, and Imagawa-Matsumoto syndrome patients (Cohen and Gibson, 2016; Tatton-Brown et al., 2011; Cooney et al., 2017; Imagawa et al., 2017; Tatton-Brown et al., 2013), and similar outcomes have been observed in mouse offspring lacking EED in oocytes (Prokopuk et al., 2018), further work may provide insights into these rare human conditions.
Methods
Mouse strains, animal care, and ethics
Mice were housed using a 12 hr light-dark cycle at Monash Medical Centre Animal Facility, as previously reported (Prokopuk et al., 2018). Room temperature was maintained at 21–23°C with controlled humidity, and food and water were provided ad libitum. All animal work was undertaken in accordance with Monash University Animal Ethics Committee (AEC) approvals. Mice were obtained from the following sources: Zp3Cre mice C57BL/6-Tg 93knw/J; Jackson Labs line 003651, constructed and shared by Professor Barbara Knowles (de Vries et al., 2000), Eed floxed mice (Eedfl/fl) B6; 129S1-Eedtm1Sho/J; Jackson Labs line 0022727; constructed and shared by Professor Stuart Orkin (Yu et al., 2009). The Eed line was backcrossed to a pure C57BL6/J and shared with us by Associate Professor Rhys Allen and Professor Marnie Blewitt, Walter and Eliza Hall Institute for Medical Research, Melbourne.
Genotyping
Genotyping was performed by Transnetyx (Cordova, TN) using real-time PCR assays (details available upon request) designed for each gene as described previously (Prokopuk et al., 2018).
Collection and culture of pre-implantation embryos
Eight to twelve-week-old female mice were superovulated and mated to C57BL/6 males for one night. Zygotes were collected in handling media (G-MOPS PLUS, Vitrolife) at 37 °C (Gardner and Lane, 2014; Gardner and Truong, 2019) denuded of cumulus cells with G-MOPS PLUS containing hyaluronidase. All embryos were washed in G-MOPS PLUS and embryo development kinetics was assessed using the EmbryoScope (Vitrolife) time-lapse imaging system. Embryos were cultured individually in 25 μl of medium, with time-lapse images generated at 15 minute (min) intervals throughout the culture period.
Cell allocation in blastocysts
Following EmbryoScope culture, differential staining was performed (Hardy et al., 1989) in hatched blastocysts using propidium iodide to label TE nuclei, while leaving the ICM unlabelled. After fixation, embryos were treated with bisbenzimide to stain ICM and TE, whole-mounted in glycerol, and imaged using an inverted fluorescence microscope (Nikon Eclipse TS100). Nuclei were counted using ImageJ.
Collection of post-implantation embryos, placenta, and postnatal offspring
Mice were time mated for two-four nights, with females plug checked daily for copulation plugs. Positive plugs were noted as day E0.5 and all females for which a plug was discovered were immediately separated from the male. Gestational length was measured in days post copulation by recording the morning of a copulation plug was detected as E0.5 and visually monitoring females twice daily (morning and afternoon) for births from late gestation (E18.5) until pups were delivered (E19.5-E21.5, depending on oocyte genotype). Pregnant females were euthanised and embryos were collected at E9.5, E12.5 E14.5, E17.5, and E18.5. E9.5 whole sacs were weighed, fixed in 4% PFA for 72 hr at 4 °C, processed, paraffin-embedded, and sectioned at 5 µm. Whole-mount images of E9.5 embryos were taken using a LEICA M80 light microscope with LEICA MC170 HD camera attachment. Embryos and placentas were collected from the same offspring at E12.5, E14.5, E17.5, and E18.5 and weighed separately. Placentas were then bisected, and half was fixed in 4% PFA for 72 hr at 4 °C, processed, and paraffin-embedded with the cut side of the placenta facing the front of the block. The other half of the placenta was rinsed in PBS, snap-frozen on dry ice, and stored at –80 °C for RNA analysis and RRBS. P0 (day of birth) or P3 pups were weighed, euthanised by decapitation, and samples collected as required.
Placental histology
Each block was trimmed to the minimum extent possible to allow collection of full placental sections. Blocks were sectioned in compound series at 5 µm using a Leica microtome and sections transferred to Superfrost plus slides (Thermo Fisher Scientific). With as much accuracy as possible, every section was collected, starting from the midline of each placenta. Two slides at the start of the series were used for H&E and PAS staining and slides from the remaining set were used for PLAC1 immunohistochemistry and CD31 immunofluorescence. Periodic antigen-shiff (PAS) and hematoxylin and eosin (H&E) staining were performed by the Monash Histology Platform (MHTP node) and the H&E and PAS-stained slides and were scanned using an Aperio slide scanner. Quantitative histological analysis was conducted on one complete, intact section located as close to the midline of each placenta as possible. Decidua and junctional zones were histologically identified and the area of each calculated in sections of E14.5 and E17.5 H&E-stained placentas using QuPath v0.2.3 (Bankhead et al., 2017). QuPath was also trained to identify glycogen-enriched and non-enriched cells using a small subsection WT-wt, HET-het, and HET-hom placental sections. Once a robust protocol had been established, machine-learning assisted image analysis provided by QuPath v0.2.3 (Bankhead et al., 2017) was used to quantify Glycogen cell and non-glycogen enriched cells in the junctional zone and decidua in fully intact midline sections of 10 (five male and five female) E14.5 and E17.5 placentas from WT-wt, WT-het, HET-het, and HET-hom mice. Investigators were blinded for sample genotypes throughout quantitative scoring of placental samples analysed.
Immunohistochemistry and image analysis
Slides with 5 µm thick placental sections (described in placental histology) were baked at 60 °C for 20 min. Tissue sections were dewaxed in three changes of xylene and rehydrated in three changes of ethanol then rinsed in distilled water. Antigen retrieval was performed in DAKO PT Link in a DAKO Target Retrieval (Low pH) Solution (DAKO, Cat# S1699) at 98 °C for 30 min. Slides were then washed in DAKO EnVision Flex Wash Buffer (Cat# K8000) for 5 min. IHC was then performed on a DAKO Autostainer Plus in the following steps. Sections were washed once in EnVision Flex Wash Buffer following each subsequent step. Peroxidase Blocking Solution (DAKO, Cat# S2023) was applied for 10 min and non-specific binding was prevented with AffiniPure Fab Fragment Goat Anti-Mouse IgG for 1 hr. Mouse anti-PLAC1 (G-1) (Santa Cruz, Cat# sc-365919) primary antibody was diluted 1/100 in PBS containing 0.1% Triton X-100 (PBST) and 1% Bovine Serum Albumin (BSA, Merck) and applied to the sections for 1 hr. EnVision System-HRP Labelled Polymer Anti-Mouse (DAKO, Cat# K4001) was applied for 1 hr. Immunostaining was visualised using DAKO Liquid DAB + Substrate Chromogen System (Cat# K3468). A counterstain DAKO Automation Haematoxylin Staining Reagent was then applied for 10 min. Slides were removed from the Autostainer, transferred to a slide staining rack, and rinsed in distilled water. In a fume-hood, slides were then washed in Scott’s Tap water and distilled water. Finally, slides were dehydrated in three changes of 100% Ethanol, cleared in three changes of Xylene, and mounted in DPX. Slides were scanned using a VS120 slide scanner (Olympus).
Immunofluorescence and image analysis
Placental sections were de-waxed and processed for antigen retrieval as described above. Non-specific binding was blocked using 5% Bovine Serum Albumin (BSA, Merck) containing 10% Donkey Serum (Merck) for 1 hr at room temperature (RT). Block solution was replaced with PBST containing 1% BSA and goat anti-CD31 antibody (1/100, R&D Systems) and incubated overnight at 4 °C. Samples were washed three times in PBS before incubation with PBST containing 1% BSA and Donkey anti-Goat IgG (H+L) Cross-Adsorbed secondary antibody (Alexa Fluor 555, Thermo Fisher Scientific) for 1 hr at RT. Samples were washed three times in PBS, followed by incubation with TrueView Autofluorescence Quenching Kit (Vector Laboratories) for 5 min at RT according to the manufacturer’s instructions. Following three washes in PBS, samples were incubated in dH2O containing 5 µg/ml DAPI (4',6-Diamidino-2-Phenylindole, Dilactate, Thermo Fisher Scientific) for 15 min at RT. Samples were washed a final three times in PBS, rinsed in dH2O, and mounted in Vectashield Vibrance Antifade Mounting Medium (Vector Laboratories). Slides were scanned using the VS120 Slide scanner (Olympus). Quantification of blood vessels, labyrinth area, and capillary area was achieved using machine learning-assisted image analysis using HALO (Indica Labs). Initially, HALO was trained to recognise the labyrinth area based on CD31 positive capillary staining and to exclude larger blood vessels and other tissue (e.g. the chorionic plate), which were easily distinguishable (Figure 5B). Then HALO was trained to calculate the area of the labyrinth occupied by CD31-positive blood vessels. Once training was complete, HALO was used to analyse all sections across 24 slides (described in placental histology) from male and female placentas of WT-wt, HET-het, and HET-hom placentas. Data was annotated in excel and statistically analysed using One-way ANOVA plus Tukey’s multiple comparisons in GraphPad Prism.
Placental RNA-sequencing and data analyses
Placental isolation is described above. RNA was extracted from 3 to 5 E17.5 placentas of both sexes for each genotype using NucleoSpin RNA Plus columns. RNA quality was assessed on an Agilent Bioanalyser and samples with RIN >7.5 used for library preparation and sequencing on the BGI Genomics platform (BGI Genomics, Hong Kong). Adaptor and low-quality sequences in raw sequencing reads were trimmed using Trimmomatic (Bolger et al., 2014) (v0.39) with the following parameters: LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:20. Clean reads were mapped to the mouse reference genome (GRCm38) using STAR (v2.7.5c) with the following settings: outFilterMismatchNoverLmax 0.03 --alignIntronMax 10000. Raw counts for mouse reference genes (ensembl-release-101) were calculated using STAR (v2.7.5c) with parameter ‘--quantMode GeneCounts’ simultaneously when doing the genome mapping. Differential gene expression analysis was carried out using the R package ‘limma’ (Ritchie et al., 2015) with ‘treat’ function and parameter ‘lfc = log(1.1).’ Statistically significantly differentially expressed genes were identified using ‘FDR <0.05.’ Gene Ontology (GO) enrichment analysis for significantly differentially expressed genes was carried out using The Database for Annotation, Visualisation, and Integrated Discovery (DAVID) with the following settings: GO term level 3, minimum gene count 5, and FDR <0.05 (Dennis et al., 2003).
Placental reduced representation bisulphite sequencing (RRBS)
5 WT-wt, 5 HET-het, and 6 HET-hom placentas from female E17.5 mice were chosen for RRBS. DNA was extracted from a quarter of each placenta with a Qiagen DNeasy Blood & Tissue Kit and eluted in AE buffer (10 mM Tris-HCl, 0.5 mM EDTA). 4–13 μg of DNA was sent to CD Genomics (NY, USA) and underwent sodium bisulphite conversion, library preparation, and Illumina PE150 sequencing at 10 Gb raw data per sample. Sequence analyses were performed on the Galaxy Australia Bioinformatics Platform (https://usegalaxy.org.au/) (Afgan et al., 2022). Sequence files were aligned to the GRC39 (mm39) mouse genome with BWA-meth. Per-base CpG methylation metrics were extracted with MethylDackel with the output limited to CpG sites with a minimum of five reads coverage with output presented as CpG methylation fractions. Differentially methylated CpG-rich regions (DMRs) between the groups were identified with Metilene with settings of a minimum of 10 CpGs per DMR and a minimum of 10% methylation difference between groups. Statistically significant DMRs which were below the threshold of Bonferroni adjusted p-value of q<0.05 were examined further. DMR regions were visualised and nearby genes and orthologous genome regions identified with the UCSC Genome Browser (https://genome.ucsc.edu/ with Table Browser and LiftOver tools) or Ensemble Biomart (https://asia.ensembl.org/info/data/biomart/index.html).
Metabolomics
E17.5 fetuses were isolated from pregnant females and decapitated on ice. ~50 ul of blood was collected from each fetus using a pipette and transferred into tubes containing 2 ul 0.5 M EDTA. collected by centrifugation and frozen at –80 C before metabolic analysis. Cardiac blood and serum samples were also collected from the mothers of each litter using the same approach. In addition, a spot of blood collected in the same way from each fetus and mother was directly applied to an Accu-Check Blood Glucose Test Strips and glucose concentration quantified using an Accu-Check Monitor. Mass spectrometry was performed on 10 ul of serum by Metabolomics Australia and included targeted profiling of 356 metabolites using the Shimadzu GCMS 8050 system. 1 ul of each sample was injected and analysed using internal standards 13C5, 15N1 Valine, and 13C6 Sorbitol. 85 samples and 19 pooled blood quality controls (PBQCs) were analysed, with PBQCs used to ensure technical consistency of the instrument and sample quantifications. Samples were analysed in randomised order, with a PBQC run after every five samples. 160 metabolites were detected with 85% resulting in a coefficient of variation of <30%. Data was analysed using Metaboanalyst 5.0 to assess data quality and multivariate analyses were used to generate principal component analyses, heatmap, and volcano plots. Statistical differences between samples were assessed using an FDR <0.05 to ensure differences detected with 95% confidence after multiple comparisons correction.
Data availability
All RNA sequencing and RRBS data have been deposited to the Gene Expression Omnibus (GEO) and are publicly available with accession number GSE210398. The metabolomics data are available at the NIH Common Fund’s National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has been assigned Study ID ST003211. The data can be accessed directly via its Project DOI: http://doi.org/10.21228/M8TR5T. Data for Figures 6 and 8 are included in Supplementary file 1.
-
NCBI Gene Expression OmnibusID GSE210398. Fetal growth delay caused by loss of non-canonical imprinting is resolved late in pregnancy and culminates in offspring overgrowth.
-
Metabolomics WorkbenchFetal growth delay caused by loss of non-canonical imprinting is resolved late in pregnancy and culminates in offspring overgrowth.https://doi.org/10.21228/M8TR5T
References
-
The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2022 updateNucleic Acids Research 50:W345–W351.https://doi.org/10.1093/nar/gkac247
-
Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics 30:2114–2120.https://doi.org/10.1093/bioinformatics/btu170
-
EED-associated overgrowth in a second male patientJournal of Human Genetics 61:831–834.https://doi.org/10.1038/jhg.2016.51
-
Adaptations of the human placenta to hypoxia: opportunities for interventions in fetal growth restrictionHuman Reproduction Update 27:531–569.https://doi.org/10.1093/humupd/dmaa053
-
Novel EED mutation in patient with weaver syndromeAmerican Journal of Medical Genetics. Part A 173:541–545.https://doi.org/10.1002/ajmg.a.38055
-
DAVID: database for annotation, visualization, and integrated discoveryGenome Biology 4:P3.
-
Expression of cre recombinase in mouse oocytes: a means to study maternal effect genesGenesis 26:110–112.
-
Epigenetic control of skeletal development by the histone methyltransferase ezh2The Journal of Biological Chemistry 290:27604–27617.https://doi.org/10.1074/jbc.M115.672345
-
BookMammalian Preimplantation embryo cultureIn: Lewandoski M, editors. Mouse Molecular Embryology: Methods and Protocols. Boston, MA: Springer US. pp. 167–182.https://doi.org/10.1007/978-1-60327-292-6_11
-
Culture of the mouse preimplantation embryoMethods in Molecular Biology 2006:13–32.https://doi.org/10.1007/978-1-4939-9566-0_2
-
Structural basis for PRC2 engagement with chromatinCurrent Opinion in Structural Biology 67:135–144.https://doi.org/10.1016/j.sbi.2020.10.017
-
Features and mechanisms of canonical and noncanonical genomic imprintingGenes & Development 35:821–834.https://doi.org/10.1101/gad.348422.121
-
Novel SUZ12 mutations in weaver-like syndromeClinical Genetics 94:461–466.https://doi.org/10.1111/cge.13415
-
Plac1 (placenta-specific 1) is essential for normal placental and embryonic developmentMolecular Reproduction and Development 79:564–572.https://doi.org/10.1002/mrd.22062
-
Epigenetics in the placentaAmerican Journal of Reproductive Immunology 62:78–89.https://doi.org/10.1111/j.1600-0897.2009.00716.x
-
The polycomb-group gene Ezh2 is required for early mouse developmentMolecular and Cellular Biology 21:4330–4336.https://doi.org/10.1128/MCB.21.13.4330-4336.2001
-
Loss of maternal EED results in postnatal overgrowthClinical Epigenetics 10:95.https://doi.org/10.1186/s13148-018-0526-8
-
Reduced expression of netrin-1 is associated with fetal growth restrictionMolecular and Cellular Biochemistry 350:81–87.https://doi.org/10.1007/s11010-010-0684-2
-
Long-term adverse effects of early growth acceleration or catch-up growthAnnals of Nutrition & Metabolism 70:236–240.https://doi.org/10.1159/000464302
-
Chromatin and epigenetic rearrangements in embryonic stem cell fate transitionsFrontiers in Cell and Developmental Biology 9:637309.https://doi.org/10.3389/fcell.2021.637309
-
Weaver syndrome and EZH2 mutations: clarifying the clinical phenotypeAmerican Journal of Medical Genetics. Part A 161A:2972–2980.https://doi.org/10.1002/ajmg.a.36229
-
Peg3 deficiency results in sexually dimorphic losses and gains in the normal repertoire of placental hormonesFrontiers in Cell and Developmental Biology 6:123.https://doi.org/10.3389/fcell.2018.00123
-
Role of axonal guidance factor netrin-1 in human placental vascular growthJournal of Huazhong University of Science and Technology. Medical Sciences 31:246–250.https://doi.org/10.1007/s11596-011-0261-2
Article and author information
Author details
Funding
National Health and Medical Research Council (GNT1144966)
- Patrick S Western
- David K Gardner
- Maarten van den Buuse
- David L Adelson
National Health and Medical Research Council (GNT1144887)
- Patrick S Western
- David K Gardner
- David L Adelson
National Health and Medical Research Council (GNT2021247)
- Patrick S Western
- David L Adelson
Australian Government (Research Training Program Scholarship)
- Ellen G Jarred
- Ruby Oberin
- Sigrid Petautschnig
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank A/Prof John McBain for generously supporting this work. We also thank Prof. Marnie Blewitt for critical comments on the manuscript, the Hudson Institute Animal Research Platform staff for assistance with mouse care, the Monash Histology Platform for assistance with sample preparation and slide scanning, and the Monash Micro Imaging Facility and Hudson Genomics Facility for assistance and technical advice. This project used NCRIS-enabled Metabolomics Australia infrastructure at the University of Melbourne and funded through BioPlatforms Australia. We would like to thank Dr. David De Souza and Dr. Nadeem Elahee Doomun for their advice and for running the metabolomics analyses in this study. This work was supported by grants and research funds from: National Health and Medical Research Project and Ideas Grants GNT1144966 (PSW, DKG, MvdB, DLA), GNT1144887 (PSW, DKG, DLA), and GNT2021247 (PSW, DLA), Hudson Institute of Medical Research, Victorian Government’s Operational Infrastructure Support Program, Australian Government Research Training Program Scholarship support to EGJ, RO, and SP, and a philanthropic donation from Associate Professor John McBain. Metabolomics Workbench is supported by NIH U2C-DK119886 and OT2-OD030544.
Ethics
All animal work was undertaken in accordance with Monash University Animal Ethics Committee (AEC) approvals issued by Monash University and Hudson Institute Animal Ethics Committees (AEC), approval numbers MMCB/2018/16 and MMCB/2020/37.
Copyright
© 2024, Oberin, Petautschnig et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 392
- views
-
- 68
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Developmental Biology
- Neuroscience
The blood-brain barrier (BBB) controls the movement of molecules into and out of the central nervous system (CNS). Since a functional BBB forms by mouse embryonic day E15.5, we reasoned that gene cohorts expressed in CNS endothelial cells (EC) at E13.5 contribute to BBB formation. In contrast, adult gene signatures reflect BBB maintenance mechanisms. Supporting this hypothesis, transcriptomic analysis revealed distinct cohorts of EC genes involved in BBB formation and maintenance. Here, we demonstrate that epigenetic regulator’s histone deacetylase 2 (HDAC2) and polycomb repressive complex 2 (PRC2) control EC gene expression for BBB development and prevent Wnt/β-catenin (Wnt) target genes from being expressed in adult CNS ECs. Low Wnt activity during development modifies BBB genes epigenetically for the formation of functional BBB. As a Class-I HDAC inhibitor induces adult CNS ECs to regain Wnt activity and BBB genetic signatures that support BBB formation, our results inform strategies to promote BBB repair.
-
- Developmental Biology
The structural integrity of the sperm is crucial for male fertility, defects in sperm head-tail linkage and flagellar axoneme are associated with acephalic spermatozoa syndrome (ASS) and the multiple morphological abnormalities of the sperm flagella (MMAF). Notably, impaired head-tail coupling apparatus (HTCA) often accompanies defects in the flagellum structure, however, the molecular mechanisms underlying this phenomenon remain elusive. Here, we identified an evolutionarily conserved coiled-coil domain-containing (CCDC) protein, CCDC113, and found the disruption of CCDC113 produced spermatozoa with disorganized sperm flagella and HTCA, which caused male infertility. Further analysis revealed that CCDC113 could bind to CFAP57 and CFAP91, and function as an adaptor protein for the connection of radial spokes, nexin-dynein regulatory complex (N-DRC), and doublet microtubules (DMTs) in the sperm axoneme. Moreover, CCDC113 was identified as a structural component of HTCA, collaborating with SUN5 and CENTLEIN to connect sperm head to tail during spermiogenesis. Together, our studies reveal that CCDC113 serve as a critical hub for sperm axoneme and HTCA stabilization in mice, providing insights into the potential pathogenesis of infertility associated with human CCDC113 mutations.